Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

The T-win® technology: immune-modulating vaccines

(2018) Mads Hald Andersen   Seminars in Immunopathology

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

(2018) Alexander J. Muller et al.   Seminars in Immunopathology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report

(2018) Julie Westerlin Kjeldsen et al.   Frontiers in Immunology

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves

(2018) David P. Enot et al.   OncoImmunology

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

(2017) James L. Gulley et al.   JNCI-Journal of the National Cancer Institute

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

(2017) James L. Gulley et al.   JNCI-Journal of the National Cancer Institute

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab

(2016) Jon Bjoern et al.   CYTOTHERAPY

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy

(2015) M. H. Andersen   JNCI-Journal of the National Cancer Institute

Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy

(2015) M. H. Andersen   JNCI-Journal of the National Cancer Institute

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

(2013) T. Z. Iversen et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

(2010) R. B. Sorensen et al.   BLOOD

Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate

(2010) A. J. Muller et al.   CANCER RESEARCH

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

(2010) H. K. Koblish et al.   MOLECULAR CANCER THERAPEUTICS

B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase

(2010) B. A. Johnson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic vaccines in solid tumours: Can they be harmful?

(2009) Alexander M.M. Eggermont   EUROPEAN JOURNAL OF CANCER

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase

(2009) Rikke Bæk Sørensen et al.   PLoS One

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

(2008) A. J. Muller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA